Lancet: The Lancet new article consolidates the status of aspirin "god medicine" and can reduce the risk of colorectal cancer in two years

In scientific research, there is never a shortage of "myths" about aspirinSince its birth more than 100 years ago, researchers have been trying to apply the magic drug topreventionand treatment sedatives, including cancer, which is talkable1988, researchers at the University of Melbourne revealed the protective effects of aspirin oncolorectal cancerpatients, and more and more researchers began to explore the cancer prevention properties of aspirinRecently, a study published in the international journalLancetadds evidence to the anti-cancer potential of aspirina study led by researchers at the University of Newcastle in the UK, taking 600 mg of aspirin a day for two years significantly reduces the risk of colorectal cancer in people with Lynch syndrome, and this protective effect lasts for at least 20 yearsLynch syndrome, also known historically as hereditary non-polylocent colorectal cancer (HNPCC), is a dominant genetic disease caused mainly by mismatched genetic mutations, often from the age of 50What's scary about it is that not only does it make patients more susceptible to colorectal cancer, endometrial cancer and other diseases, but cancer tends to progress faster, such as the development of adenoma in the colorectal to adenocarcinoma in the general population for 8 to 10 years, while people with Lynch syndrome only need 2 to 3 years or so, the probability of re-onset after surgery is very highto help people with Lynch syndrome prevent disease, the 1999 Cancer Prevention Program (CaPP) was launched, the main result of which was to observe the number, size and histological phaseof of colorectal cancer detected at least 2 years after the aspirin intervention, and the secondary clinical result sized and numerous cancers associated with Lynch syndromebetween January 1999 and March 2005, a total of 861 people with Lynch syndrome participated in the study, of whom 427 received oral 600 mg of intestinally soluble aspirin daily, 434 received 30 g Novelose placebo treatment, each group undertook approximately 25 months of drug intervention and followed up on that basis for more than seven yearsFollow-up results showed that about 5 years after the start of aspirin treatment, the incidence of colorectal cancer began to vary and the low incidence of cancer was maintained throughout the observation period overall, 40 people (9%) in the aspirin group developed the disease in terms of the prevalence of colorectal cancer, compared with 58 (13%) in the placebo group When all cancer types were taken into account, the data were 74 (17%) and 89 (21%) for the aspirin and placebo groups, respectively the intentional treatment analysis showed a 35 percent reduction in the risk ratio (HR) in the aspirin and placebo groups, and 44 percent lower in patients who took the drug for at least two years The protective effects of aspirin have continued for 20 years Overall, the study showed that taking 600 mg of aspirin a day reduced the risk of colorectal cancer in people at high risk At the same time, the report notes that the effective dose of aspirin is still uncertain, and researchers will explore this in a follow-up study